172470-04-1

Basic information

• Product Name: 3-Pyridinecarboxylic acid,5-ethyl-1,2-dihydro-4-hydroxy-6-methyl-2-oxo-, ethyl ester
• Synonyms: 3-Pyridinecarboxylic acid,5-ethyl-1,2-dihydro-4-hydroxy-6-methyl-2-oxo-, ethyl ester;5-Ethyl-4-hydroxy-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid ethyl ester;Ethyl 5-ethyl-4-hydroxy-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxylate
• CAS NO: 172470-04-1
• Molecular Formula: C₁₁H₁₅NO₄
• Molecular Weight: 225.2411
• Mol File: 172470-04-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinecarboxylic acid,5-ethyl-1,2-dihydro-4-hydroxy-6-methyl-2-oxo-, ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarboxylic acid,5-ethyl-1,2-dihydro-4-hydroxy-6-methyl-2-oxo-, ethyl ester(172470-04-1)
• EPA Substance Registry System: 3-Pyridinecarboxylic acid,5-ethyl-1,2-dihydro-4-hydroxy-6-methyl-2-oxo-, ethyl ester(172470-04-1)

Safety Data

• Hazardous Substances Data: 172470-04-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl nicotinate is used as an active ingredient in topical creams and ointments for the treatment of conditions such as eczema, psoriasis, and arthritis. Its vasodilatory and anti-inflammatory properties help alleviate the symptoms of these conditions.
Used in Cosmetic Industry:
Ethyl nicotinate is used as a fragrance ingredient in the cosmetic industry. Its pleasant scent and anti-inflammatory properties make it a valuable addition to various cosmetic products.
Used in Food Industry:
Ethyl nicotinate is used as a flavoring agent in the food industry. Its unique taste and aroma enhance the flavor of various food products.
Used in Research:
Ethyl nicotinate has been studied for its potential therapeutic effects on cardiovascular and metabolic disorders. Its vasodilatory properties may help improve blood flow and reduce inflammation, making it a promising candidate for further research and development in these areas.

Upstream product

• 55788-92-6 ethyl 2-ethyl-3-aminocrotonate 
• 105-53-3 diethyl malonate 
• 42805-39-0 ethyl (Z)-3-amino-2-ethyl-but-2-enoate 
• 607-97-6 ethyl 2-ethyl-3-oxobutanoate 
• 1606976-44-6 ethyl (Z)-3-[(3-ethoxy-3-oxo-propanoyl)amino]-2-ethyl-but-2-enoate 

Downstream Products

• 14159-59-2 2-methyl-3-ethyl-pyridine 
• 929080-34-2 4-(3,5-dimethyl-phenoxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carbaldehyde 
• 929080-31-9 4-(3,5-dimethyl-phenoxy)-5-ethyl-3-hydroxymethyl-6-methyl-1H-pyridin-2-one 
• 929080-41-1 4-(3,5-dimethyl-phenoxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid 
• 651778-59-5 4-(3,5-dimethyl-phenoxy)-5-ethyl-6-methyl-1H-pyridin-2-one 
• 651778-58-4 4-(3,5-dimethyl-phenoxy)-5-ethyl-6-methyl-2-oxo-1,2-dihydro-pyridine-3-carboxylic acid ethyl ester 
• 172470-05-2 5-ethyl-6-methyl-4-(3', 5'-dimethylphenyl)thio-pyridin-2(1H)-one 
• 172469-94-2 3-amino-5-ethyl-6-methyl-4-(3', 5'-dimethylphenyl)thio-pyridin-2(1H)-one 
• 172469-78-2 5-ethyl-6-methyl-3-nitro-4-(3', 5'-dimethylphenyl)thio-pyridin-2(1H)-one 
• 172469-91-9 5-ethyl-6-methyl-3-carbethoxy-4-(3', 5'-dimethylphenyl)thio-pyridin-2(1H)-one 

Relevant articles and documents

HETEROARYL INHIBITORS OF PDE4

The present invention relates to compounds and methods useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of disease.

New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Several 5-ethyl-6-methyl-4-cycloalkyloxy-pyridin-2(1H)-ones were synthesized and evaluated for their anti HIV-1 activities against wild-type virus and clinically relevant mutant strains. A racemic mixture (10) with methyl substituents at positions 3 and 5

2-pyridinone derivatives, having HIV inhibiting properties

The present invention relates to 2-Pyridinone derivatives, more specifically 5-ethyl-6-methyl-2-pyridinone derivatives, according to general formula I that inhibit human immunodeficiency virus type 1 (HIV-1) replication and are therefore of interest in th

4-Aryl-thio-pyridin-2(1H)-ones, medicines containing them and their uses in the treatment of illnesses linked to HIV

PCT No. PCT/FR96/01204 Sec. 371 Date Apr. 15, 1998 Sec. 102(e) Date Apr. 15, 1998 PCT Filed Jul. 30, 1996 PCT Pub. No. WO97/05113 PCT Pub. Date Feb. 13, 1997Compounds of formula (3) in which: R1 and R2 independently represent an atom of hydrogen, an aliphatic group or an alkyloxyalkyl group in which the alkyl chains are from C1 to C4 or together form an aromatic ring; R3 represents: an atom of hydrogen, or an NHR5 group in which R5 represents an atom of hydrogen or a COR6 group in which R6 is an aliphatic or aromatic group, or an NO2 group or a COOR7 group in which R7 is an aliphatic group, R4 represents a phenyl or heterocyclic group. These compounds can be used in the treatment of illnesses linked to the HIV virus.

A new series of pyridinone derivatives as potent non-nucleoside human immunodeficiency virus type 1 specific reverse transcriptase inhibitors

4-(Arylthio)-pyridin-2(1H)-ones variously substituted in their 3-, 5-, and 6-positions have been synthesized as a new series of 1-[(2- hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT)-pyridinone hybrid molecules. Biological studies revealed that some of them show potent HIV-1 specific reverse transcriptase inhibitory properties. Compounds 16 and 7c, the most active ones, inhibit the replication of HIV-1 at 3 and 6 nM, respectively.